EUVIMEDAtrasti EUVIMED
Crossref

Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors

Lev Gorfinkel iD, Emily M Harris iD, Catherine B Wall, Allison F O'Neill iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.32011 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2025. Written by Lev Gorfinkel and 3 co-authors. Institution: Dana-Farber and Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Recombinant Fusion Proteins, Thrombopoietin, Thrombocytopenia, Receptors, Fc. Cited 2 times so far (Crossref); 26 references.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Romiplostim for chemotherapy‐induced thrombocytopenia (CIT) is not well‐studied in children. This single‐center retrospective cohort study describes 24 pediatric patients with solid tumors who initiated romiplostim a median of 5 months into chemotherapy (range: 0–14 months) at a median maximum dose of 6.5 µg/kg (range: 1–10). A minority of patients achieved a decrease in cycle delays (30%) or dose reductions (13%). A comparative cohort, which did not receive romiplostim, had no difference in cycle delays ( p = 0.42) or dose reductions ( p > 0.99). There were no adverse events. Romiplostim was safe in children with solid tumors, but requires further prospective study of efficacy.

Subjects

MeSH terms (MEDLINE)

Recombinant Fusion ProteinsThrombopoietinThrombocytopeniaReceptors, FcNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansMaleFemaleChildChild, PreschoolRetrospective StudiesInfantAdolescentFollow-Up StudiesPrognosis

Author keywords

chemotherapy‐induced thrombocytopeniapediatricromiplostimsolid tumor

Substances

romiplostimRecombinant Fusion ProteinsThrombopoietinReceptors, FcAntineoplastic Agents

Authors and institutions

  • Dana-Farber and Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.

ORCID profiles: Lev Gorfinkel, Emily M Harris, Allison F O'Neill

Cite

APA

Gorfinkel, L., Harris, E. M., Wall, C. B., & O'Neill, A. F. (2025). Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32011

Vancouver

Gorfinkel L, Harris EM, Wall CB, O'Neill AF. Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32011

BibTeX
@article{Gorfinkel2025,
  author = {Gorfinkel, Lev and Harris, Emily M and Wall, Catherine B and O'Neill, Allison F},
  title = {Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.32011}
}
Start for free →